leflunomide
Selected indexed studies
- Leflunomide: Traditional immunosuppressant with concurrent antiviral effects. (Int J Rheum Dis, 2023) [PMID:36371788]
- Leflunomide nanocarriers: a new prospect of therapeutic applications. (J Microencapsul, 2024) [PMID:39320955]
- Leflunomide. (Rheum Dis Clin North Am, 2004) [PMID:15172042]
_Worker-drafted node — pending editorial review._
Connections
leflunomide is a side effect of
Sources
- Leflunomide: Traditional immunosuppressant with concurrent antiviral effects. (2023) pubmed
- Leflunomide nanocarriers: a new prospect of therapeutic applications. (2024) pubmed
- Leflunomide. (2004) pubmed
- Leflunomide-Associated Pancytopenia. (2023) pubmed
- Antirheumatic drug leflunomide attenuates atherosclerosis by regulating lipid metabolism and endothelial dysfunction via DHODH/AMPK signaling pathway. (2024) pubmed
- Leflunomide and methotrexate. (2001) pubmed
- Leflunomide: A promising drug with good antitumor potential. (2018) pubmed
- Leflunomide-induced collagenous colitis: a case report and literature review. (2024) pubmed
- Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up. (2022) pubmed
- Leflunomide. (2003) pubmed